Broadly neutralizing antibody PGDM1400 (PGDM1400) (PGDM1400)

PGDM1400 is a human IgG1 broadly neutralizing monoclonal antibody designed to target the glycan-dependent V2 apex region of the HIV-1 envelope glycoprotein trimer (centered at glycan N160). Isolated from a chronically HIV-infected donor, PGDM1400 demonstrates exceptional breadth and potency, neutralizing 83% of tested HIV strains at low concentrations (median IC50 of 0.003 µg/mL). It has been studied as a candidate for both HIV treatment and prophylaxis, either as monotherapy or in combination with other bnAbs (PGT121, VRC07-523LS, etc.) in preclinical animal challenge models and early-phase human clinical trials. As a therapeutic, its mechanisms include direct viral neutralization, Fc-effector functions (ADCC, phagocytosis), and potential engagement of innate immunity. Although PGDM1400 is itself a therapeutic antibody rather than a traditional drug target, its molecular target—the V2 apex of the HIV Env—is a key focus for passive immunotherapy and vaccine development against HIV.

Other names

PGDM1400

Direct binding to V2 apex region of HIV-1 Env trimer (glycan at N160); Blocks viral entry by inhibiting Env-mediated fusion; Engages Fc-receptors to mediate ADCC and phagocytosis; Passive immunization (direct administration of antibody, not induced by vaccination)